Combined with a study on MB-MDA-231 (medium FcRn), SPEDOX-6’s antitumor efficacy displays an inverse relationship with FcRn levels in three tumor mouse models, thereby providing a potential mechanism for SPEDOX-6 to effectively target tumors with low FcRn levels. This evidence concerns the gene FCGRT and neoplasm.